Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34+Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD)

MLA

Orchard, Paul, et al. “Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34+Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD).” Blood, vol. 132, no. 1, Number 1 Supplement 1, Nov. 2018, p. 3467. EBSCOhost, https://doi.org/10.1182/blood-2018-99-115102.

APA

Orchard, P., Raffel, G. D., Condon, C. H., Monaghan, C. A., Vernet, D., Sheirr, S. T., Braun, J., Shanley, R., Lund, T. C., Boitano, A. E., Cooke, M. P., Davis, J. C., & Wagner, J. E. (2018). Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34+Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD). Blood, 132(1, Number 1 Supplement 1), 3467. https://doi.org/10.1182/blood-2018-99-115102

Chicago

Orchard, Paul, Glen D. Raffel, Carolyn H Condon, Catherine A Monaghan, Demetra Vernet, Suzanne Tracey Sheirr, Jennifer Braun, et al. 2018. “Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34+Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD).” Blood 132 (1, Number 1 Supplement 1): 3467. doi:10.1182/blood-2018-99-115102.